Universal Beteiligungs und Servicegesellschaft mbH Buys New Shares in Emergent Biosolutions Inc. (NYSE:EBS)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH acquired 96,700 shares of Emergent Biosolutions Inc. during the first quarter, representing an investment of approximately $470,000.
• A number of institutional investors increased their stakes in Emergent Biosolutions, with Covestor Ltd raising its stake by 5,458.5% and now owning 2,946 shares.
• Emergent Biosolutions' stock is currently down 4.3%, with a recent price of $5.63 and a market capitalization of $305.60 million.

Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Emergent Biosolutions Inc. (NYSE:EBS - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 96,700 shares of the biopharmaceutical company's stock, valued at approximately $470,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.18% of Emergent Biosolutions as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently bought and sold shares of EBS. LPL Financial LLC boosted its holdings in Emergent Biosolutions by 34.5% during the 4th quarter. LPL Financial LLC now owns 15,120 shares of the biopharmaceutical company's stock valued at $145,000 after acquiring an additional 3,875 shares during the period. Geode Capital Management LLC grew its position in Emergent Biosolutions by 1.5% during the fourth quarter. Geode Capital Management LLC now owns 590,862 shares of the biopharmaceutical company's stock valued at $5,651,000 after buying an additional 8,904 shares during the period. Landscape Capital Management L.L.C. raised its position in Emergent Biosolutions by 39.5% during the fourth quarter. Landscape Capital Management L.L.C. now owns 23,595 shares of the biopharmaceutical company's stock worth $226,000 after acquiring an additional 6,682 shares during the period. Envestnet Asset Management Inc. acquired a new stake in Emergent Biosolutions during the 4th quarter worth $331,000. Finally, Federated Hermes Inc. boosted its holdings in Emergent Biosolutions by 2.2% in the 4th quarter. Federated Hermes Inc. now owns 277,810 shares of the biopharmaceutical company's stock valued at $2,656,000 after purchasing an additional 6,058 shares during the last quarter. Hedge funds and other institutional investors own 78.40% of the company's stock.

Insider Buying and Selling

In other Emergent Biosolutions news, Director Keith Katkin sold 7,844 shares of the company's stock in a transaction on Friday, May 23rd. The stock was sold at an average price of $6.30, for a total value of $49,417.20. Following the transaction, the director owned 86,431 shares of the company's stock, valued at approximately $544,515.30. This represents a 8.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.20% of the company's stock.

Emergent Biosolutions Stock Down 0.7%

NYSE EBS traded down $0.04 during trading hours on Wednesday, hitting $6.06. 885,690 shares of the company were exchanged, compared to its average volume of 1,088,038. The company has a quick ratio of 3.51, a current ratio of 6.32 and a debt-to-equity ratio of 1.20. The company has a 50 day moving average of $6.64 and a two-hundred day moving average of $6.70. The firm has a market cap of $328.72 million, a price-to-earnings ratio of -2.23 and a beta of 1.97. Emergent Biosolutions Inc. has a 52-week low of $4.02 and a 52-week high of $13.28.

Emergent Biosolutions (NYSE:EBS - Get Free Report) last issued its earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.16 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.21 by ($0.05). Emergent Biosolutions had a negative return on equity of 0.52% and a negative net margin of 13.63%. Equities research analysts anticipate that Emergent Biosolutions Inc. will post -0.63 earnings per share for the current year.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.